INTRODUCTION

A good functioning AV fistula or graft is directly linked to improved quality of life of patients on hemodialysis. Access problems are common and frequent reason of hospitalisation for these patients. The most common issues of hemodialysis accesses are poor flow, thrombosis, bleeding or inadequate dialysis due to central venous stenosis (CVS).

About 11% to 40% of the patients on hemodialysis have CVS. Patients with previous history of central line placement and having AV access on the ipsilateral arm are at risk of developing CVS. Patients may present with severe arm, neck, and breast oedema. They also have malfunctioning accesses with inadequate dialysis.

Over the last two decades, percutaneous methods have taken over the surgery for treatment of CVS due to their minimal invasiveness. They are considered to be effective in improving the patency of failing AV accesses, and also relieving patient's symptoms. There is little reported in loco-regional literature on the outcomes of these procedures.

The objective of this study was to determine the success of percutaneous venoplasty in terms of relieving symptoms of CVS and improving the patency of AV accesses.

METHODOLOGY

This was a retrospective study conducted at the Aga Khan University Hospital from January 2012 to December 2017. All patients, who had CVS in upper arm or lower leg, were included in the study. Patients who were lost to follow-up or had incomplete records were excluded from the study. Data about patients' demographics, symptoms, existing co-morbidities, indication for CVS intervention, and location of lesion were retrieved and recorded on specially designed proforma.

All patients had standard percutaneous venoplasties with plain balloons. Technical success was considered when there was less than 30% residual stenosis. Stenting was
considered in patients when residual stenosis of more than 50%, with elastic recoil or with complication. Patients were monitored for any post-procedure complications such as bleeding, access site hematoma or access thrombosis. Patients were allowed to use accesses soon after the procedure, if needed. Patients were followed in vascular surgery clinics at 3-month interval.

The outcomes measured were symptomatic recovery and improvement in the patency of arteriovenous access. Symptomatic recovery was termed 'complete', when there was complete symptomatic relief after venoplasty; and 'partial' when the procedure was technically successful but symptoms that led to venoplasty, were not resolved.

Patency of AV accesses were measured as primary and cumulative patency. Primary patency was the duration of time from first intervention to next intervention or fistula failure. Cumulative patency was the total duration of time fistula remain, patent with multiple interventions.

Events considered end points to functional access status were placement of new access site, ligation of access site, dialysis catheter placement or the patient death.

Categorical variables were reported as frequencies along with their percentages. Continuous variables were reported as mean ± standard deviation. Patency rate was calculated using Kaplan-Meier survival curve. A p-value of <0.05 was considered as significant. Analyses were performed using SPSS version 22 (IBM Inc.).

RESULTS

During the study period, 48 patients had attempted venoplasty. Thirteen patients were excluded as wire was not negotiable through the lesion. Thirty-five patients had technically successful venoplasty. The mean age of the patients was 56.86 ±14.6 years. Most of them were females (21, 60%). The major comorbidities were hypertension and diabetes (Table I). Twenty-four (68.6%) patients had native arteriovenous fistula, while 11 (31.4%) had arteriovenous grafts.

Twenty-three (65.7%) patients presented with arm swelling, 10 (28.6%) patients with poor flow, and 2 (5.7%) patients with increased pressure during dialysis.

The most common sites of stenosis were brachiocephalic vein followed by subclavian vein. One patient had balloon leak, while another patient had cardiac event in post-procedure day, which settled with medical management.

Twenty-one (60%) patients had initial complete relief of symptoms and 14 (40%) patients had partial relief. Primary patency was 40%, 24%, 24% at 6, 12 and 24 months. Cumulative patency was 69%, 66% and 59% at 6, 12 and 24 months (Figures 1 and 2).

<table>
<thead>
<tr>
<th>Table I: Demographics of patients and details of arteriovenous accesses.</th>
</tr>
</thead>
<tbody>
<tr>
<td>N=35 Number (%)</td>
</tr>
<tr>
<td>Comorbidities</td>
</tr>
<tr>
<td>Hypertension 34 (97.1)</td>
</tr>
<tr>
<td>Diabetes mellitus 16 (45.7)</td>
</tr>
<tr>
<td>Coronary artery disease 8(22.9)</td>
</tr>
<tr>
<td>Hepatitis C 5(14.3)</td>
</tr>
<tr>
<td>Polycystic kidney disease 2(5.7)</td>
</tr>
<tr>
<td>Hypothyroidism 3(8.6)</td>
</tr>
<tr>
<td>Systemic lupus erythrosclerosis 3(8.6)</td>
</tr>
<tr>
<td>Site of fistula</td>
</tr>
<tr>
<td>Left arm 24 (68.6)</td>
</tr>
<tr>
<td>Right arm 9 (25.7)</td>
</tr>
<tr>
<td>Left leg 1 (2.9)</td>
</tr>
<tr>
<td>Right leg 1 (2.9)</td>
</tr>
<tr>
<td>Site of stenosis</td>
</tr>
<tr>
<td>Axillary vein 8 (22.9)</td>
</tr>
<tr>
<td>Subclavian vein 9 (25.7)</td>
</tr>
<tr>
<td>Brachiocephalic vein 16 (45.7)</td>
</tr>
<tr>
<td>External iliac vein 1 (2.9)</td>
</tr>
<tr>
<td>Common iliac vein 1 (2.9)</td>
</tr>
</tbody>
</table>

Figure 1: Graph showing primary patency of arteriovenous accesses.

Figure 2: Graph showing cumulative patency of arteriovenous accesses.
Twenty-six (74%) patients had recurrence of symptoms. Twenty-one (60%) patients underwent repeat angioplasty. Five patients (14%) had surgical management for CVS. Ligation and formation of new AVF in one patient; two patients had thrombectomies, while two patients had bypass procedures for relieving CVS. Four patients had stents placed. One stent was placed at the time of first angioplasty and three were placed at the time of the repeated venoplasty sessions.

**DISCUSSION**

The present study showed that CVS venoplasty improved patients’ symptoms and also improved the short term patency of vascular access. Seventy-four percent patients had recurrence in which most patients required repeated venoplasty. There were no major complication encountered. All accesses were usable for dialysis soon after the procedure.

Bakken et al. showed improved haemodialysis access patency of 77%, 73% and 57% at 3, 12 and 24 months after CVS venoplasty. Bountouris et al. also noted patency of 42% at 24 months. Glanz S et al. noted 1-year patency rate of 35%. The results are consistent with this study. Ya et al. showed, PTA for CVC achieved technical success in 92% of cases, and symptoms were initially alleviated in 96% of subjects. Others have also documented the efficiency of this modality. The authors also found it effective in relieving patients arm swelling.

Plain balloons were used but better patency may be achievable with cutting balloons, drug-eluting balloons, or specialised high pressure balloons. These were neither available nor feasible due to higher cost.

The use of stents is controversial during intervention. Many authors have highlighted the issue of recurrence after initial venoplasty and considered it a norm. Ya et al. showed recurrence rate of 58% at 4 months after PTA. Same were the findings of the Sprouse et al. and Argarwal et al. Inflating the balloon itself caused local intimal injury and may induce neointimal hyperplasia, hence recurrent venous stenosis.

Many authors have reviewed the role of stenting in stenotic lesions. Many of the previous studies fail to demonstrate whether stenting provides additional benefit or not. Stents were offered only to those patients who had elastic recoil or had significant persistent stenosis. There have been studies which document better patency rates following stenting. However, long term patency is not seen in all cases. Quinn et al. compared stenting with PTA alone and saw that patency rates were comparative in both cases. Oderich et al. reported that primary patency remains same at one year and re-intervention rate is not better than the presently reported results.

The limitations of this study include being a retrospective, collection of data from a single institute with limited number of patients. Despite this, it showed the efficiency of PTA in relieving arm oedema and improving short term longevity of AV accesses.

**CONCLUSION**

Percutaneous venoplasty for CVS can provide symptomatic relief in majority of the patients and can improve the short term patency of arteriovenous access.

**ETHICAL APPROVAL:**

Being a retrospective study, it was exempted from Institutional Ethical Review Committee approval.

**PATIENTS’ CONSENT:**

All patients gave informed consent for using of their data for research purpose at the time of index procedure.

**CONFLICT OF INTEREST:**

Authors declared no conflict of interest.

**AUTHORS’ CONTRIBUTION:**

ZUR: Study concept, data collection and interpretation, manuscript writing, revision, critical review, final approval and accountability of all aspects of the work.

AH: Data collection and interpretation, manuscript writing, final approval and accountability of all aspects of the work.

RS: Critical review, final approval and accountability of all aspects of the work.

NZ: Data Interpretation, final approval and accountability of all aspects of the work.

**REFERENCES**


